相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin β3/SRC pathway
Wenyi Zhang et al.
ONCOGENE (2021)
YAP/TAZ functions and their regulation at a glance
Arianna Pocaterra et al.
JOURNAL OF CELL SCIENCE (2020)
Epidermal Growth Factor Receptor Mutations
Erin M. McLoughlin et al.
THORACIC SURGERY CLINICS (2020)
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
Monique B. Nilsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance
Jonathan Cooper et al.
CANCER CELL (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells
Adviti Naik et al.
BMC CANCER (2018)
Axl inhibitors as novel cancer therapeutic agents
Yingying Shen et al.
LIFE SCIENCES (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer
Soon-Ki Hong et al.
MOLECULAR CANCER (2018)
Every step of the way: integrins in cancer progression and metastasis
Hellyeh Hamidi et al.
NATURE REVIEWS CANCER (2018)
Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3
Ning Zhang et al.
JOURNAL OF CANCER (2017)
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
Elena Ghiso et al.
NEOPLASIA (2017)
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Erika Cosset et al.
CANCER CELL (2017)
Giving AXL the axe: targeting AXL in human malignancy
Carl M. Gay et al.
BRITISH JOURNAL OF CANCER (2017)
Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
Jeong Eun Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Induction of integrin β3 by sustained ERK activity promotes the invasiveness of TGFβ-induced mesenchymal tumor cells
Soon-Ki Hong et al.
CANCER LETTERS (2016)
Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Cristina Corno et al.
CURRENT MEDICINAL CHEMISTRY (2016)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Floriana Morgillo et al.
ESMO OPEN (2016)
Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
Katia Rea et al.
ONCOTARGET (2015)
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson et al.
CANCER RESEARCH (2014)
The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
Juliano D. Paccez et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Cilengitide in glioblastoma: when did it fail?
Olivier L. Chinot
LANCET ONCOLOGY (2014)
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Laetitia Seguin et al.
NATURE CELL BIOLOGY (2014)
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
Christian Manegold et al.
INVESTIGATIONAL NEW DRUGS (2013)
First Axl inhibitor enters clinical trials
Cormac Sheridan
NATURE BIOTECHNOLOGY (2013)
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Ajjai Alva et al.
INVESTIGATIONAL NEW DRUGS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Carlos Mas-Moruno et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
An integrin αvβ3-c-Src oncogenic unit promotes anchorage-independence and tumor progression
Jay S. Desgrosellier et al.
NATURE MEDICINE (2009)
Axl receptor activation mediates laminar shear stress anti-apoptotic effects in human endothelial cells
Daniela D'Arcangelo et al.
CARDIOVASCULAR RESEARCH (2006)
分享论文
